...
首页> 外文期刊>Scandinavian journal of urology >Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study
【24h】

Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study

机译:北欧四个国家男性人口中非那雄胺的使用方式:一项跨国药物利用研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective Finasteride 5 mg is a drug used to treat prostate hyperplasia. Little is known about its pattern of usage. This cross-national analysis of individual-level data from Denmark, Finland, Norway and Sweden was undertaken to appraise its usage and describe cross-national differences. Materials and methods Individual-level data from nationwide prescription registers in Denmark (1995-2009), Finland (1997-2010), Norway (2004-2009) and Sweden (July 2005-2011) were used to examine cross-national finasteride utilization patterns in the adult male population (>= 15 years). The study presents period prevalences, incidence rates, waiting time distributions and Lorenz curves. Results During the study period, 295,620 men had at least one prescription redemption of finasteride 5 mg, and there were approximately 3 million dispensing events of finasteride prescriptions in the four Nordic countries. Different patterns of finasteride use were observed among the four Nordic countries. The period prevalence was markedly higher in Finland and Sweden than in Denmark and Norway. In 2009, period prevalences were 18.2/1000 males in Finland and 12.0/1000 males in Sweden compared to 6.7/1000 males in Norway and 4.9/1000 males in Denmark. Incidence rates of finasteride use for Finland, Norway and Sweden were about three times that for Denmark in 2008-2009. Long-term use of finasteride was found in all four Nordic countries with a high ratio between prevalent and incident users. Conclusion Despite resemblances regarding political systems and healthcare services in the Nordic countries, differences in finasteride utilization were found across Denmark, Finland, Norway and Sweden.
机译:目标非那雄胺5毫克是用于治疗前列腺增生的药物。对其使用方式知之甚少。对丹麦,芬兰,挪威和瑞典的个人数据进行了跨国分析,以评估其用途并描述跨国差异。材料和方法使用来自丹麦(1995-2009),芬兰(1997-2010),挪威(2004-2009)和瑞典(2005-2011年7月)全国处方登记簿的个人水平数据来检验跨国非那雄胺的利用模式在成年男性人口中(> = 15岁)。该研究提出了期间患病率,发病率,等待时间分布和洛伦兹曲线。结果在研究期间,有295,620名男性至少有一次赎回非那雄胺5 mg处方,并且在四个北欧国家中大约有300万次非那雄胺处方的分发事件。在四个北欧国家中观察到了不同的非那雄胺使用方式。芬兰和瑞典的时期患病率明显高于丹麦和挪威。 2009年,芬兰的期间患病率为18.2 / 1000男性,瑞典为12.0 / 1000男性,而挪威为6.7 / 1000男性,丹麦为4.9 / 1000。 2008-2009年,芬兰,挪威和瑞典使用非那雄胺的发生率约为丹麦的三倍。在所有四个北欧国家中,长期使用非那雄胺的人群中普遍使用和非处方使用的比率很高。结论尽管北欧国家在政治制度和医疗服​​务方面存在相似之处,但在丹麦,芬兰,挪威和瑞典发现非那雄胺的利用存在差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号